0GT Stock Overview
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Stoke Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.30 |
52 Week High | US$12.40 |
52 Week Low | US$3.16 |
Beta | 0.67 |
1 Month Change | 93.75% |
3 Month Change | 99.57% |
1 Year Change | 27.40% |
3 Year Change | -69.41% |
5 Year Change | n/a |
Change since IPO | -61.60% |
Recent News & Updates
Recent updates
Shareholder Returns
0GT | DE Biotechs | DE Market | |
---|---|---|---|
7D | 70.6% | 2.1% | 1.9% |
1Y | 27.4% | 37.0% | 7.3% |
Return vs Industry: 0GT underperformed the German Biotechs industry which returned 35.8% over the past year.
Return vs Market: 0GT exceeded the German Market which returned 6.4% over the past year.
Price Volatility
0GT volatility | |
---|---|
0GT Average Weekly Movement | 23.2% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0GT's share price has been volatile over the past 3 months.
Volatility Over Time: 0GT's weekly volatility has increased from 15% to 23% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 110 | Ed Kaye | https://www.stoketherapeutics.com |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.
Stoke Therapeutics, Inc. Fundamentals Summary
0GT fundamental statistics | |
---|---|
Market cap | €277.89m |
Earnings (TTM) | -€96.67m |
Revenue (TTM) | €8.11m |
54.3x
P/S Ratio-4.6x
P/E RatioIs 0GT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0GT income statement (TTM) | |
---|---|
Revenue | US$8.78m |
Cost of Revenue | US$0 |
Gross Profit | US$8.78m |
Other Expenses | US$113.48m |
Earnings | -US$104.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.26 |
Gross Margin | 100.00% |
Net Profit Margin | -1,192.47% |
Debt/Equity Ratio | 0% |
How did 0GT perform over the long term?
See historical performance and comparison